IPCA Laboratories
Pranay Godha currently serves as the Managing Director and CEO of Ipca Laboratories Limited, a position held since April 2023. Prior to this role, Pranay held various leadership positions at Ipca Laboratories, including Executive Director and President of APIs and Generics, contributing to the company's success from 2001 to April 2023. Additional experience includes serving as a Board Member at Kaygee-Loparex India Pvt. Ltd. from January 1997 to August 2015. Pranay Godha's educational background includes an MBA in International Marketing from the New York Institute of Technology (1993-1995) and a B.Sc. in Microbiology from the University of Mumbai (1989-1992).
This person is not in the org chart
IPCA Laboratories
3 followers
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs). It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax. Its 3c division focuses on cardiovascular and anti-diabetic markets. Its 3d division is focused on cardio-diabetic market. The Company's activa division serves the rheumatology market. Its altus division caters to the needs of intensivists, both surgical and non-surgical. Its Bionova division's focus area is dermatology. Its dynamix division focuses on cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory sectors. It hycare division caters to the needs of cardiologists and diabetologists. Its divisions also include innova, intima, pain management, pharma and uro sciences.